Successful, we will reply to you quickly.OK
Please select the quantity.OK
Your message is being sent, please wait.Close
Send mail failed, please send again!Close
Products are for research use only. Not for human use. We do not sell to patients.
CPDA Chemical Structure
|Product name: CPDA|
|Cat. No.: HY-18685|
CPDA is a novel potent SHIP2 inhibitor that can effectively ameliorate insulin resistance in 3T3-L1 adipocytes.
in vitro: CPDA was found to enhance insulin signaling.
in vivo: CPDA greatly improves abnormal glucose metabolism in diabetic animals. CPDA was also found to improve the abnormal glucose metabolism in db/db mice.
|M.Wt||388.8||Storage||Please store the product under the recommended conditions in the Certificate of Analysis.|
|Solvent & Solubility||
10 mM in DMSO
|1 mg||5 mg||10 mg|
|1 mM||2.5720 mL||12.8601 mL||25.7202 mL|
|5 mM||0.5144 mL||2.5720 mL||5.1440 mL|
|10 mM||0.2572 mL||1.2860 mL||2.5720 mL|
A-770041 is selective and orally active Src-family Lck inhibitor; A-770041 is a 147 nM inhibitor of Lck (1 mM ATP) and is 300-fold selective against Fyn, the other Src family kinase involved in T-cell signaling.
AMG-47a is a potent inhibitor of Lck and T cell proliferation; exhibits anti-inflammatory activity (ED50 = 11 mg/kg) in the anti-CD3 induced production of IL-2 in mice.
AZM475271 is a potent and selective Src kinase inhibitor with IC50 of 5 nM; no inhibitory activity on Flt3, KDR, Tie-2.
Bosutinib is Src family kinase inhibitor. Bosutinib inhibited migration of breast cancer cell lines with IC50 values of 0.1 to 0.3 umol/L.
DCC-2036(Rebastinib) is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit.
KX1-004 is a potent small molecule inhibitor of Src-PTK as a potential protective drug for NIHL.
MCB-613 is a potent, pan steroid receptor coactivator (SRC) stimulator.
MNS is a potent and selective inhibitor of Src and Syk tyrosine kinases.
PD173955 is src family-selective tyrosine kinase inhibitor with IC50 of ~22 nM for Src, Yes and Abl kinase; less potent for FGFR(alpha) and no activity on InsR and PKC.
Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFR(alpha), VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM, respectively.